Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma

Cited by papers we hold 6

• Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives · 2024
  No notice
• Exploring treatment options in cancer: tumor treatment strategies · 2024
  No notice
• Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses · 2022
  No notice
• Tumor microenvironment: barrier or opportunity towards effective cancer therapy · 2022
  No notice
• HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy · 2021
  No notice
• Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.